MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 05-07-2026
BioNTech SE EPS Ratio 2011-2026 | BNTX
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio BioNTech SE
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.7 | -2.77 | 3.87 | 38.8 | 42.2 | 0.06 | -0.85 | -0.25 | -0.51 | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 42.2 | -4.7 | 8.42 |
Quarterly EPS Ratio BioNTech SE
| 2025-Q4 | 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.7 | -2.77 | 3.87 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.87 | -4.7 | -1.2 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
0.75 | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-1.91 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M | China |
 |
Coherus BioSciences
CHRS
|
1.43 | $ 1.63 | -4.4 % | $ 191 M | USA |
 |
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
1.51 | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
6.6 | - | - | $ 96.9 B |  Britain |
 |
Enlivex Therapeutics Ltd.
ENLV
|
27 | $ 0.73 | -0.03 % | $ 33.4 M |  Israel |
 |
Arcturus Therapeutics Holdings
ARCT
|
-2.4 | $ 7.83 | -5.21 % | $ 214 M | Israel |
 |
Athira Pharma
ATHA
|
-24.7 | - | - | $ 269 M | USA |
 |
Esperion Therapeutics
ESPR
|
-0.11 | $ 3.12 | - | $ 649 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-0.07 | - | 0.74 % | $ 768 M | Israel |
 |
Exelixis
EXEL
|
2.88 | $ 51.1 | -0.37 % | $ 13.9 B | USA |
|
Forte Biosciences
FBRX
|
-4.71 | $ 23.96 | -2.84 % | $ 310 M | USA |
|
Galera Therapeutics
GRTX
|
0.64 | - | -32.59 % | $ 7.61 M | USA |
 |
Karyopharm Therapeutics
KPTI
|
-17.9 | $ 8.9 | 0.56 % | $ 1.08 M | USA |
 |
AbCellera Biologics
ABCL
|
-0.49 | $ 4.4 | -7.76 % | $ 1.31 B |  Canada |
 |
Midatech Pharma plc
MTP
|
-0.0001 | - | -18.52 % | $ 27.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
2.1 | $ 17.3 | -5.57 % | $ 809 M | USA |
 |
Compugen Ltd.
CGEN
|
0.38 | $ 3.03 | 6.32 % | $ 283 M | Israel |
 |
Checkmate Pharmaceuticals
CMPI
|
-2.84 | - | - | $ 231 M | USA |
 |
Gilead Sciences
GILD
|
6.84 | $ 132.06 | -0.74 % | $ 164 B | USA |
 |
Genmab A/S
GMAB
|
122 | $ 26.9 | 1.32 % | $ 1.74 B |  Danmark |
 |
Genprex
GNPX
|
-17.4 | $ 0.86 | 1.2 % | $ 802 K | USA |
 |
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-5.97 | $ 3.49 | -4.12 % | $ 5.75 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-3.27 | - | 5.93 % | $ 314 M | Canada |
 |
Grifols, S.A.
GRFS
|
0.23 | $ 7.79 | 1.04 % | $ 5.29 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-1.57 | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-10.4 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | USA |
 |
Fortress Biotech
FBIO
|
-0.07 | $ 2.3 | 3.14 % | $ 64.2 M | USA |
 |
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-2.85 | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-2.14 | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-0.13 | $ 21.57 | -0.55 % | $ 2.74 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-0.34 | $ 9.24 | 36.48 % | $ 264 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | USA |